Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines

Pharmaceutical Research

Volumn 17, Issue 1, 2000, Pages 42-48

  Van Slooten, M L ^a   Storm, G ^a   Zoephel, A ^b   Kupcu Z ^b   Boerman, O ^c   Crommelin, D J A ^a   Wagner, E ^b   Kircheis, R ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer vaccines; Cytokines; Gene transfer; Immunotherapy; Interferon gamma; Liposomes

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; LIPOSOME; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; FEMALE; IMMUNE RESPONSE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; DRUG CARRIERS; FEMALE; INTERFERON TYPE II; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINATION;

EID: 0034006659     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007514424253     Document Type: Article

References (30)

1. 1. N. P. Restifo and M. Sznol. Cancer Vaccines. In V. T. De Vita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Lippincott-Raven, Philadelphia, 1997, 5th ed. pp. 3023-3043.
2. 2. J. R. Quesada, M. Talpaz, A. Rios, R. Kurzrock, and J. U. Gutterman. Clinical toxicity of interferons in cancer patients: a review. J. Clin. Oncol. 4:234-243 (1986).
3. 3. M. B. Atkins and E. G. Trehu. Combination cytokine therapy. In V. T. De Vita, S. Hellman, and S. A. Rosenberg (eds.), Biologic therapy of cancer, J. B. Lippincott Company, Philadelphia, 1995, 2nd ed. pp. 443-466.
4. 4. R. Kircheis, Z. Küpcü, G. Wallner, and E. Wagner. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFNγ, or combination IL-2 + IFNγ. Cytokines, Cell. Mol. Ther. 4:95-103 (1998).
5. 5. A. Porgador, B. Gansbacher, R. Bannerji, et al. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int. J. Cancer 53:471-477 (1993).
6. 6. G. Maass, T. Schweighoffer, M. Berger, et al. Tumor vaccines: effect and fate of IL-2 transfected murine melanoma cells in vivo. Int. J. Immunopharmac. 17:65-73 (1995).
7. 7. K. Zatloukal, A. Schneeberger, M. Berger, et al. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J. Immunol. 154:3406-3419 (1995).
8. 8. P. Nanni, C. De Giovanni, L. Landuzzi, et al. Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells. Br. J. Cancer 74:1564-1569 (1996).
9. 9. G. Dranoff, E. Jaffee, A. Lazenby, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90:3539-3543 (1993).
10. 10. G. Storm, H. P. Wilms, and D. J. Crommelin. Liposomes and biotherapeutics. Biotherapy 3:25-42 (1991).
11. 11. G. Storm, F. J. Koppenhagen, A. Heeremans, M. H. Vingerhoeds, M. C. Woodle, and D. J. Crommelin. Liposomal delivery of peptides and proteins. J. Liposome Research 5:481-489 (1995).
12. 12. E. Kedar, O. Palgi, G. Golod, I. Babai, and Y. Barenholz. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. J. Immunother. 20:180-193 (1997).
13. 13. S. Hockertz, G. Franke, I. Paulini, and M. L. Lohmann-Matthes. Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes. J. Interferon. Res. 11:177-185 (1991).
14. 14. A. E. Bolton and W. M. Hunter. The labelling of proteins to high specific radioactivities by conjugation to a 1251-containing acylating agent. Biochem. J. 133:529-538 (1973).
15. 15. E. Wagner, K. Zatloukal, M. Cotten, et al. Coupling of adenovirus to polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc. Natl. Acad. Sci. U.S.A. 89:6099-6013 (1992).
16. 16. U. K. Nassander, G. Storm, P. A. M. Peeters, and D. J. Crommelin. Liposomes. In M. Chasim, R. Langer (eds.), Biodegradable polymers as drug delivery systems, Marcel Dekker Inc. New York, 1990, pp. 261-338.
17. 17. E. G. Bligh and W. S. Dyer. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol 37:911-917 (1959).
18. 18. G. Rouser, S. Flusher, and A. Yamamoto. Two dimensional thin layer Chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5:494-496 (1970).
19. 19. H. Karasuyama and F. Melchers. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur. J. Immunol. 18:97-104 (1988).
20. 20. K. Zatloukal, W. Schmidt, M. Cotten, E. Wagner, G. Stingl, and M. L. Birnstiel. Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'. Gene 135:199-207 (1993).
21. 21. G. L. Pool, M. E. French, R. A. Edwards, L. Huang, and R. H. Lumb. Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker. Lipids 17:448-452 (1982).
22. 22. C. Oussoren, J. Zuidema, D. J. Crommelin, and G. Storm. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta 1328:261-272 (1997).
23. 23. F. J. Koppenhagen. Liposomes as delivery system for recombinant interleukin-2 in anticancer immunotherapy. Thesis. Utrecht University, Utrecht, The Netherlands. (1997)
24. 24. R. Kurzrock, M. G. Rosenblum, S. A. Sherwin, et al. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res. 45:2866-2872 (1985).
25. 25. I. Rutenfranz and H. Kirchner. Pharmacokinetics of recombinant murine interferon-gamma in mice. J. Interferon. Res. 8:573-580 (1988).
26. 26. S. Hockertz, G. Franke, E. Kniep, and M. L. Lohmann-Matthes. Mouse interferon-gamma in liposomes: pharmacokinetics, organdistribution, and activation of spleen and liver macrophages in vivo. J. Interferon. Res. 9:591-602 (1989).
27. 27. W. Schmidt, T. Schweighoffer, E. Herbst, et al. Cancer vaccines: the interleukin 2 dosage effect. Proc. Natl. Acad. Sci. U.S.A. 92:4711-4714 (1995).
28. 28. D. Berd, M. J. Mastrangelo, E. Lattime, T. Sato, and H. C. Maguire, Jr. Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunol. Immunother. 42:263-267 (1996).
29. 29. S. A. Rosenberg and D. E. White. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis. Tumor Immunol. 19:81-84 (1996).
30. 30. A. N. Houghton, S. Vijayasaradhi, B. Bouchard, C. Naftzger, I. Hara, and P. B. Chapman. Recognition of autoantigens by patients with melanoma. Ann. N. Y. Acad. Sci. 59-64 (1993).